Time course of pathologic changes in kidney allografts of positive crossmatch HLA-incompatible transplant recipients

Transplantation

Volumn 97, Issue 4, 2014, Pages 440-445

  Bagnasco, Serena M ^a   Zachary, Andrea A ^a   Racusen, Lorraine C ^a   Arend, Lois J ^a   Carter Monroe, Naima ^a   Alachkar, Nada ^a   Nazarian, Susanna M ^a   Lonze, Bonnie E ^a   Montgomery, Robert A ^a   Kraus, Edward S ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antibody mediated rejection; Glomerulopathy; Kidney; Rejection; Transplant

Indexed keywords

COMPLEMENT COMPONENT C4D; CYTOMEGALOVIRUS ANTIBODY; DACLIZUMAB; DEXAMETHASONE; HLA ANTIGEN; MYCOPHENOLIC ACID; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY;

ADULT; AGED; ANTIBODY MEDIATED REJECTION; ARTICLE; CAPILLARITIS; CELLULAR IMMUNITY; DISEASE COURSE; END STAGE RENAL DISEASE; FEMALE; GLOMERULITIS; GLOMERULOPATHY; GRAFT RECIPIENT; GRAFT SURVIVAL; HISTOINCOMPATIBILITY; HISTOPATHOLOGY; HLA MATCHING; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT REJECTION; KIDNEY BIOPSY; KIDNEY SCAR; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RENAL GRAFT DYSFUNCTION; RISK FACTOR; TRANSPLANT GLOMERULOPATHY;

ADULT; AGED; ANTIBODIES; BIOPSY; COMPLEMENT C4B; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; GRAFT SURVIVAL; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HUMANS; IMMUNOSUPPRESSION; INFLAMMATION; KIDNEY; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; MALE; MICROCIRCULATION; MIDDLE AGED; PEPTIDE FRAGMENTS; RENAL INSUFFICIENCY; RISK FACTORS; TIME FACTORS; TISSUE DONORS; YOUNG ADULT;

EID: 84896695537     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000437177.40551.f4     Document Type: Article

References (24)

1. Glotz D, Antoine C, Julia P, et al. Desensitization and subsequent kidney transplantation of patients using intravenous immunoglobulins (IVIg). Am J Transplant 2002; 2: 758
2. Montgomery RA, Locke JE, King KE, et al. ABO incompatible renal transplantation: A paradigm ready for implementation. Transplantation 2009; 87: 1246
3. Montgomery RA, Lonze BE, King KE, et al. Desensitization in HLAincompatible kidney recipients and survival. N Engl J Med 2011; 365: 318
4. Stegall MD, Gloor J,Winters JL, et al. A comparison of plasmapheresis versus high-dose IVIG desensitization in renal allograft recipients with high levels of donor specific alloantibody. Am J Transplant 2006; 6: 346
5. Mauiyyedi S, Crespo M, Collins AB, et al. Acute humoral rejection in kidney transplantation: II. Morphology, immunopathology, and pathologic classification. J Am Soc Nephrol 2002; 13: 779
6. Bentall A, Cornell LD, Gloor JM, et al. Five-year outcomes in living donor kidney transplants with a positive crossmatch. Am J Transplant 2013; 13: 76
7. Gloor JM, Cosio FG, Rea DJ, et al. Histologic findings one year after positive crossmatch or ABO blood group incompatible living donor kidney transplantation. Am J Transplant 2006; 6: 1841
8. Kraus ES, Parekh RS, Oberai P, et al. Subclinical rejection in stable positive crossmatch kidney transplant patients: Incidence and correlations. Am J Transplant 2009; 9: 1826
9. Einecke G, Sis B, Reeve J, et al. Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure. Am J Transplant 2009; 9: 2520
10. Naesens M, Kuypers DRJ, De Vusser K, et al. Chronic histological damage in early indication biopsies is an independent risk factor for late renal allograft failure. Am J Transplant 2013; 13: 86
11. Loupy A, Suberbielle-Boissel C, Hill GS, et al. Outcome of subclinical antibody-mediated rejection in kidney transplant recipients with preformed donor-specific antibodies. Am J Transplant 2009; 9: 2561
12. Loupy A, Hill GS, Suberbielle C, et al. Significance of C4d Banff scores in early protocol biopsies of kidney transplant recipients with preformed donor-specific antibodies (DSA). Am J Transplant 2011; 11: 56
13. Sis B, Jhangri GS, Riopel J, et al. A new diagnostic algorithm for antibody-mediated microcirculation inflammation in kidney transplants. Am J Transplant 2012; 12: 1168
14. Burns JM, Cornell LD, Perry DK, et al. Alloantibody levels and acute humoral rejection early after positive crossmatch kidney transplantation. Am J Transplant 2008; 8: 2684
15. Lefaucheur C, Loupy A, Vernerey D, et al. Antibody-mediated vascular rejection of kidney allografts: A population-based study. Lancet 2013; 381: 313
16. Mengel M, Sis B, HaasM, et al. Banff 2011meeting report: New concepts in antibody-mediated rejection. Am J Transplant 2012; 12: 563
17. Bagnasco SM, Tsai W, Rahman MH, et al. CD20-positive infiltrates in renal allograft biopsies with acute cellular rejection are not associated with worse graft survival. Am J Transplant 2007; 7: 1968
18. Racusen LC, Colvin RB, Solez K, et al. Antibody-mediated rejection criteriaVan addition to the Banff '97 classification of renal allograft rejection. Am J Transplant 2003; 3: 708
19. Solez K, Colvin RB, Racusen LC, et al. Banff 07 classification of renal allograft pathology: Updates and future directions. Am J Transplant 2008; 8: 753
20. Hopkins KA. The Basic Lymphocyte Microcytoxicity Test: Standard and AHG Enhancement. 4th ed.Hahn AB, Land GA, Strothman RM, editors. New York: American Society for Histocompatibility and Immunogenetics; 2001
21. Lucas D, Paparounis M, Myers L, et al. Detection of HLA class Ispecific antibodies by the QuikScreen enzyme-linked immunosorbent assay. Clin Diagn Lab Immunol 1997; 4: 252
22. Hetrick SJ, Schillinger KP, Zachary AA, et al. Impact of pronase on flow cytometric crossmatch outcome. Hum Immunol 2011; 72: 330
23. Zachary AA, Sholander JT, Houp JA, et al. Using real data for a virtual crossmatch. Hum Immunol 2009; 70: 574
24. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Ann Intern Med 1999; 130: 461